CAV protocol (CHO)

Subscribe to Selected New Research on CAV protocol

1613 relevant articles (66 outcomes, 177 trials/studies) found for this Drug

Description: chemotherapy protocol consisting of cyclophosphamide, adriamycin, vincristine; CAV refers to first source; acronym ACV refers to second source; acronym ACO II was used in Klin Wochenschr 1982;60(16):829; acronym ACO was used in Onkology 1982;5(4):174; acronym DVC was used in Gan To Kagaku Ryoho 1984;11(4):888

Also Known As:

CHO; ACO; AVC; DVC; ACO II; CADO protocol; NCI PB 93-C-125 protocol; NHL-15 protocol; VAC regimen; VDC regimen

Relationship Network

Drug Context: Research Results

Therapeutics: 6127

Drug Therapy: 124082

Combination Drug Therapy: 8615

Antineoplastic Combined Chemotherapy Protocols: 18

CAV protocol: 1613

Antineoplastic Protocols: 20

Antineoplastic Combined Chemotherapy Protocols: 18

CAV protocol: 1613

Clinical Protocols

Antineoplastic Protocols: 20

Antineoplastic Combined Chemotherapy Protocols: 18

CAV protocol: 1613

Polycyclic Compounds: 59

Aromatic Polycyclic Hydrocarbons: 617

Aminoglycosides: 1129

Heterocyclic Compounds: 25

Alkaloids: 691

Indole Alkaloids: 23

Secologanin Tryptamine Alkaloids: 49

Vinca Alkaloids: 290

Vincristine: 5794

CAV protocol: 1613

2-Ring Heterocyclic Compounds

Indoles: 70

Indole Alkaloids: 23

Secologanin Tryptamine Alkaloids: 49

Vinca Alkaloids: 290

Vincristine: 5794

CAV protocol: 1613

Experts

1.	Tseng, J-H: 1 article (09/2008)
2.	Chen, M-F: 1 article (09/2008)
3.	Chen, T-C: 1 article (09/2008)
4.	Yeh, T-S: 1 article (09/2008)
5.	Chiu, C-T: 1 article (09/2008)
6.	Jan, Y-Y: 1 article (09/2008)
7.	Chiang, J-M: 1 article (09/2008)
8.	Sherman, Christopher: 1 article (05/2008)
9.	Akoury, Hani: 1 article (05/2008)
10.	Coscoy, Laurent: 1 article (04/2008)

Related Diseases

1.	Neoplasms (Cancer) 10/01/1997 - "These changes included the significant reduction in Cho levels after therapy, indicating the transformation of tumor to necrotic tissue. " 06/01/2009 - "The use of negatively-charged chelates may lead to an underestimation of the levels of Cho present in human breast cancers, since most studies use MRS postcontrast administration. " 02/28/2009 - "In the present study, we characterized a typical sarcomatoid phenotype of SCK, and classified the other cell lines according to tumor cell differentiation (a poorly differentiated JCK, a moderately differentiated Cho-CK, and a well differentiated Choi-CK cells), both morphologically and immunocytologically. " 01/01/2007 - "Most malignant tumors in this study were characteristic of containing Cho metabolites. " 03/01/2004 - "The availability of cellular models is crucial to perform cell biology and pharmacological studies and clarify the relationship between AVC and pancreatic and biliary cancers. " Order ALL the reference details at left...
2.	Weight Loss (Weight Reduction) 03/01/2009 - "The PRO diet was more effective for FM loss and body composition improvement during initial weight loss and long-term maintenance and produced sustained reductions in TAG and increases in HDL-C compared with the CHO diet." 06/01/2009 - "Additional studies are warranted to determine whether a hypocaloric H-F diet might promote weight loss to a greater extent than the H-CHO diet while maintaining milk production." 03/01/2009 - "Using a compliance criterion of participants attaining >10% weight loss, the PRO group had more participants (31 vs. 21%) lose more weight (-16.5 +/- 1.5 vs. -12.3 +/- 0.9 kg; P < 0.01) and FM (-11.7 +/- 1.0 vs. -7.9 +/- 0.7 kg; P < 0.01) than the CHO group. " 03/01/2009 - "At 4 mo, the PRO group had lost 22% more fat mass (FM) (-5.6 +/- 0.4 kg) than the CHO group (-4.6 +/- 0.3 kg) but weight loss did not differ between groups (-8.2 +/- 0.5 kg vs. -7.0 +/- 0.5 kg; P = 0.10). " 01/01/2006 - "The extent to which genetic factors associate with the magnitude of weight loss induced by CHO restriction is unknown. " Order ALL the reference details at left...
3.	Fatigue 05/01/2003 - "Time to fatigue was significantly greater with CHO in both the 60% and 73% VO(2max) trials (14.5% and 13.5% improvement, respectively). " 05/01/1997 - "Subjects tended to feel more sleepy and less awake 2-3 h after the high-fat-low-CHO meal, and ratings of fatigue were significantly greater 3 h after the high-fat-low-CHO meal than after the low-fat-high-CHO meal. " 04/01/2002 - "MS-Test performance was also improved during the latter stages of exercise along with self-reported perceptions of fatigue (subscale of POMS) (P < 0.05) in CHO versus P. " 02/01/2008 - "The NORM CHO trial had the fewest failures at fatigue. " 01/01/2008 - "Subjects consumed either a 6.4% CHO-E solution or a placebo (PLA) in a double-blind fashion immediately before each trial (8 mL x kg(-1) BM) and at 15-min intervals (3 mL x kg(-1) BM) during intermittent high-intensity running to fatigue performed after CHO loading for 2 d. " Order ALL the reference details at left...
4.	Glioma (Gliomas) 06/01/2004 - "CONCLUSIONS: MR spectroscopy-guided biopsy was effective in obtaining a representative specimen for accurate pathological diagnosis, and the Cho/Cr ratio of MR spectra and Ki-67 labeling index were reliable predictors of glioma grade." 03/01/2004 - "Metabolite NAA/Cho and NAA/Cr ratios helped differentiate low-grade gliomas from FCDMs but did not differentiate glioma subtypes. " 11/01/2009 - "The aim of this study was to compare normalized mean and maximum levels of Cho as single parameters in the noninvasive grading of gliomas. " 06/01/2008 - "The aim of this study was to assess the metabolic activity of gliomas using (11)C-methionine (MET), [(18)F] fluorodeoxyglucose (FDG), and (11)C-choline (CHO) PET and to explore the correlation between the metabolic activity and histopathologic features. " 11/01/2001 - "A greater increment in the Cho/Cr ratio between successive studies was also noted in regrowing gliomas than for stable disease (range, 41% to 87% vs. < 32%). " Order ALL the reference details at left...
5.	Body Weight (Weight, Body) 09/01/2009 - "METHODS: Nine trained and familiarized male cyclists (mean +/- SD: 29.4 +/- 4.5 yr, 81.3 +/- 10.8 kg body weight [BW], 183.8 +/- 8.2 cm, V O2peak = 61.7 +/- 4.8 mL.kg.min) undertook three trials, with training and high CHO diet being controlled. " 02/01/2009 - "OBJECTIVE: The purpose of this study was to compare the effects of high-monounsaturated fatty acid (MUFA) and high-carbohydrate (CHO) diets on body weight and glycemic control in men and women with type 2 diabetes. " 02/01/2009 - "CONCLUSIONS: In individuals with type 2 diabetes, high-MUFA diets are an alternative to conventional lower-fat, high-CHO diets with comparable beneficial effects on body weight, body composition, cardiovascular risk factors, and glycemic control." 02/01/2009 - "For body weight and HDL-CHO, there were significant differences in mean trait values among DH-Chr Y-+/+, suggesting that Y-linked genes affect these traits. " 07/01/2008 - "The observed decrease in TG (18%) among low-CHO subjects, in contrast to the 4% increase for low-fat group, was not significant, nor were there significant differences in hs-CRP, overall dietary compliance, satiety, or the magnitude of body weight loss between groups (low-CHO group, -3.8% vs low-fat group, -1.6%). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Choline (Choline Chloride)
2.	N-acetylaspartate (N-acetyl aspartate)
3.	Glucose (Dextrose)
4.	Insulin (Novolin)
5.	Creatine
6.	Lactic Acid
7.	Lipids
8.	Protons (Proton)
9.	Oxygen
10.	Blood Glucose (Blood Sugar)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Fat-Restricted Diet (Diet, Fat Restricted)
3.	Braces
4.	Cardiopulmonary Resuscitation (CPR)
5.	Balneology

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>